Why ManKind (MNKD) Stock Is Soaring Today

NEW YORK (TheStreet) -- ManKind (MNKD) shares are spiking, up 10.6% to $11.06, on Monday after the FDA approved the company's inhaled insulin drug Afrezza.

Wall Street analysts believe that the drug could generate peak yearly sales of $600 million for the company.

Must ReadWarren Buffett's 25 Favorite Stocks

MNKD Chart

MNKD data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Mannkind in Free Fall After Changes to Insulin Product, Sales Force

Mannkind Stock Drops Following Changes to Its Insulin Product

Laser-Maker Cynosure Leads Biotech Movers Ahead of Market Open

Insulin Drug Offers Hope for MannKind